Anchor of Hope Opioid Treatment Program

Anchor of Hope Opioid Treatment Program is a SAMHSA-registered addiction-treatment facility in Dallas, TX. The facility's programming is outpatient (Outpatient, MAT), not residential. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Anchor of Hope Opioid Treatment Program

On care levels: Anchor of Hope Opioid Treatment Program is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. The critical pre-admission step is an independent clinical assessment that establishes ASAM 4e level-of-care recommendation. Admission at a facility whose offered level does not match the clinical assessment produces most misaligned-placement outcomes.

Insurance and payment

Anchor of Hope Opioid Treatment Program operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. Before admission, request a written Verification of Benefits from the facility's utilization-review team. Verbal VOB is where most post-admission cost-sharing disputes originate. Written documentation settles them.

Specialty programming

The facility's documented specialty programming includes: Adult women, Pregnant/postpartum women, Adult men. Specialty designations benefit from specific follow-up: programming hours per week, credentialed staff profile, integrated assessment protocols. Dual-diagnosis as a marketing category differs from operational specialty infrastructure.

Before you call

Three pre-admission questions for Anchor of Hope Opioid Treatment Program: (1) at what ASAM 4e level are you admitting me, and what is the clinical rationale; (2) can you provide written Verification of Benefits for my specific plan; (3) what is your MAT policy for opioid use disorder — specifically, do you continue buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.